M&G Investment Management’s Esperion Therapeutics ESPR Stock Holding History

M&G Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,273	Closed	-$255K	–	577
2021 Q3	$255K	Sell	21,273 -14,783	-41%	-$215K	﹤0.01%	713
2021 Q2	$757K	Buy	+36,056	New	+$868K	﹤0.01%	647

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

M&G Investment Management's ESPR Position: Q4 2021 in Review

M&G Investment Management sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 21,273 shares — an estimated $255K sold.

M&G Investment Management first reported a position in ESPR in Q2 2021 and held it in 2 quarters. The position peaked at $757K in Q2 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

M&G Investment Management reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
M&G Investment Management sold 21,273 Esperion Therapeutics shares in Q4 2021, an estimated $255K.
M&G Investment Management first reported a position in Esperion Therapeutics in Q2 2021 and held it in 2 quarters.
M&G Investment Management's Esperion Therapeutics position peaked at $757K in Q2 2021.
133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.